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Cardiovascular disease accounts over half of the total mortality in peritoneal dialysis (PD) patients. In addition, there is an
increasing recognition of a high prevalence of vascular and valvular calciﬁcation that may contribute to the increased all-cause
and cardiovascular mortality in the PD patients. Disturbed mineral metabolism in association with chronic kidney disease has
been suggested as one of the major contributing factors to the increased vascular/valvular calciﬁcation in this population. In this
paper,weprovideanoverviewoftheprevalenceandimportanceofthiscomplicationinthePDpatients.Inaddition,wereviewthe
contributing factors and some emerging mechanisms for this complication. Furthermore, we discuss some therapeutic strategies
that may be useful in limiting the progression of vascular/valvular calciﬁcation in the PD population.
1.Introduction
Cardiovascular disease is the leading cause of death in
end-stage renal disease (ESRD) patients receiving long-term
peritoneal dialysis (PD) therapy. Data from the Canada and
United States (CANUSA) Peritoneal Dialysis Study showed
that nearly half of the mortality in PD patients was due
to cardiovascular disease [1]. According to data from the
United State Renal Data System (USRDS), this trend has
remained more or less the same in the recent years [2].
Vascular/valvular calciﬁcations are important and highly
prevalent complications in ESRD patients including those
receiving PD therapy and very much contributed to the
exceedingly high cardiovascular mortality in this population.
Numerous observational cohort studies demonstrated the
prognostic importance of vascular/valvular calciﬁcation in
ESRD patients. Using plain radiographs to estimate number
of arterial sites with calciﬁcation including carotid artery,
abdominal aorta, and iliofemoral axis, both the presence
and extent of vascular calciﬁcations are strong predictors of
cardiovascular and all-cause mortality in the ESRD patients
[3]. Abdominal aortic calciﬁcation detected nonquantita-
tivelyusingplainlateralabdominalradiographshasalsobeen
shown to be an independent predictor of all-cause mortality
and cardiovascular death in hemodialysis patients [4]. Using
multislice computed tomography (MSCT) that enables
quantiﬁcation of calciﬁcation, Block et al. demonstrated a
signiﬁcant mortality eﬀect of the severity of coronary artery
calcium score in incident hemodialysis patients [5]. Cardiac
valvular calciﬁcation, detected using echocardiography, also
predicts all-cause mortality and cardiovascular death in
chronic PD patients. Notably, patients with both aortic
and mitral valvular calciﬁcation showed the highest risk of
mortality and cardiovascular death compared to those with
either heart valve calciﬁcation or no valve calciﬁcation [6].
These data suggest that the presence of vascular or valvular
calciﬁcation, irrespective of the sites involved, is indicative
of a poor prognosis in the dialysis population including
patients on PD. In this paper, we reviewed the prevalence,
signiﬁcance,contributingfactors,andemergingmechanisms
for this important complication in the PD population.
Furthermore,wediscussedtherapeuticstrategiesthatmaybe
useful in retarding calciﬁcation burden in the PD patients.
2. Prevalence of Vascular andValvular
Cal c iﬁ c atio ninPDP atie nts
The reported prevalence of coronary artery calciﬁcation in
the ESRD patients ranged from 40% to nearly 100% [7–14].
So far, a majority of the studies were done in hemodialysis2 International Journal of Nephrology
patients. There are very little data in PD patients but
the available evidence suggest that vascular and valvular
calciﬁcation is an equally highly prevalent complication in
the PD population. In two small surveys, at least 60% to 80%
of the PD patients, were complicated with coronary artery
calciﬁcation [15, 16]. The prevalence of cardiac valvular
calciﬁcationrangesfrom32%to47%inPDpatients[17,18],
in contrast to 19% to 84% in hemodialysis patients [19–24].
3. Signiﬁcanceof Vascular/Valvular
Cal c iﬁ c atio ninPDP atie nts
In the general population, coronary artery calcium score
provides a quantitative estimate of total atherosclerotic
plaque burden and correlates with obstructive coronary
artery disease [25]. In nondialysis chronic kidney disease
(CKD) patients, similar association was observed between
the severity of coronary artery calcium score and obstructive
coronary artery disease [26]. Study in hemodialysis patients
demonstrated a close relation between the severity of
coronary artery calciﬁcation and prevalence of atheroscle-
rotic vascular disease [10]. This is in keeping with recent
similar analysis in PD patients showing that the severity
of coronary artery calcium score was associated with the
prevalence of atherosclerotic vascular disease (unpublished
observation). On the other hand, the severity of coronary
artery calcium score is predictive of arterial stiﬀening in
patients with CKD [27] and is associated with increased risk
of left ventricular hypertrophy [28]. Unlike in the general
population, where calciﬁcation occurs mainly in the intimal
layer and reﬂects atherosclerotic disease burden, vascular
calciﬁcation in ESRD patients typically occurs both in the
intimal and medial layer [29]. The medial calciﬁcation,
known as Monckeberg’s medial calcinosis is also prominent
in patients with diabetes. Medical calciﬁcation promotes
arterial stiﬀening and is associated with increased risk of left
ventricular hypertrophy and impaired coronary perfusion
[30]. While both medial and intimal type of calciﬁcations
predict mortality and cardiovascular death in ESRD patients,
intimal calciﬁcation was associated with worse survival
compared to medial calciﬁcation [14]. On the other hand,
cardiac valvular calciﬁcation is a marker reﬂecting general-
ized atherosclerosis and calciﬁcation in the PD patients [31].
4. ClinicalCourseof Vascular/Valvular
Calciﬁcation in Long-Term PD Patients
Vascular calciﬁcation is a progressive and actively mediated
disease. Goodman et al. showed in a cohort of young
hemodialysis adults of rapid progression in coronary artery
calciﬁcation over a mean follow-up period of 20 months
[8]. In the subsequent study by Block et al., patients who
hadbaselinecoronaryarterycalciﬁcationsshowedsigniﬁcant
progression in coronary calciﬁcation while those without
baseline calciﬁcation remained free from calciﬁcation during
follow-up [32]. These data suggest that preexisting coronary
arterycalciﬁcationisoneofthekeyfactorspredictingfurther
progression of vascular calciﬁcation in ESRD patients. Our
recent analysis also reported similar ﬁnding in PD patients
(unpublished observation) in that PD patients without
signiﬁcant baseline vascular calciﬁcation remained relatively
free of calciﬁcation with time on dialysis. These data raised
the possibility of some protective mechanisms or genetic
factorsinplaythatpreventpatientsfromdevelopingvascular
calciﬁcation.
5. ContributingFactors to Vascular/Valvular
Cal c iﬁ c atio ninPDP atie nts
The high incidence of vascular/valvular calciﬁcation in
PD patients is contributed by both traditional and so-
called nontraditional or kidney disease-related risk factors.
Age is one of the major clinical factors associated with
vascular/valvular calciﬁcation in dialysis patients [7, 10,
17, 33]. Some studies showed that the degree of coronary
or valvular calciﬁcation increased with increasing duration
of dialysis [7, 8, 17]. Disturbed mineral metabolism with
resulting hyperphosphatemia has been suggested to play a
major contributing role for vascular/valvular calciﬁcation in
ESRD patients [8, 10, 12, 17]. According to a retrospective
analysis from the USRDS, an elevated serum phosphorus
or an elevated calcium × phosphorus product predicts
all-cause mortality as well as cardiovascular mortality in
hemodialysis patients [34]. Notably, patients with a high
serum phosphorus ≥6.5mg/dL was associated with an
increased risk of death from coronary artery disease, sudden
death, infection or other causes, compared with the low
phosphorus group [34]. The Netherlands Cooperative Study
on the Adequacy of Dialysis (NECOSAD) study compared
hemodialysis and PD patients and showed that hyper-
phosphatemia with resulting high calcium ∗ phosphorus
product had similar predictive value for mortality in PD
and hemodialysis patients [35]. Having a serum phosphorus
level >1.78mmol/L was associated with a time-dependent
adjustedhazardratiosof1.6and1.4forall-causemortalityin
PDandhemodialysispatients,respectively.Thesedataclearly
indicated that optimizing phosphorus control is equally
important in PD as in hemodialysis patients.
In vitro study showed that inorganic phosphate induced
an osteoblastic phenotypic change in vascular smooth
muscle cells which led to the deposition of calcium and
phosphate-containing apatite crystals[36]. This is in keeping
with cross-sectional studies demonstrating an association
between hyperphosphatemia and vascular calciﬁcation in
ESRD patients [8, 10, 12, 33]. Hyperphosphatemia is also
associated with an increased risk of valvular calciﬁcation in
patients on PD [17]. Previous longitudinal study showed
a signiﬁcant association between serum phosphorus and
calcium × phosphorus product with changes in coronary
artery calciﬁcation over 1 year in PD patients [37], providing
further evidence to support the involvement of hyperphos-
phatemia in vascular/valvular calciﬁcation in PD patients.
As in hemodialysis patients, PD patients have a
high prevalence of hyperphosphatemia. According to the
NECOSAD study, around 40% of the long-term PD patients
had serum phosphorus level above the Kidney Disease
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and was similar to that of hemodialysis patients (50%) [35].
This is very similar to our survey showing that around
40% of Chinese PD patients had serum phosphorus level
above the K/DOQI target [38]. One of the major clinical
factors associated with hyperphosphatemia in PD patients
was dietary protein intake. Residual renal function is the
other signiﬁcant factor associated with serum phosphorus
control in PD patients. Its importance outweighed that of
PD clearance among those with preserved residual kidney
function. On the other hand, among anuric PD patients,
serum phosphorus showed the strongest correlation with
PD clearance followed by normalized dietary protein intake
[38]. Additionally, a total urea clearance of at least 2.0
and creatinine clearance of at least 60L/wk per 1.73m2
appearedtobeoptimalclearancetargetsthatmaintainserum
phosphorus below 5mg/dL in continuous ambulatory PD
patients. Given that it is extremely diﬃcult to achieve a total
weekly creatinine clearance of over 60L with PD alone, these
data suggest potential limitation of PD alone to achieve ade-
quate phosphorus control in anuric PD patients. In keeping
with these observations, our recent study demonstrated an
increased prevalence of valvular calciﬁcation among anuric
PD patients and was partly mediated via an increased
calcium ∗ phosphorus product [39].
Apart from alterations in phosphorus metabolism,
some of the therapeutic strategies for abnormal mineral
metabolism and renal bone disease have been suggested
to have the potential of worsening vascular calciﬁcation in
ESRD patients [8, 40]. The use of very high doses of calcium-
based binders for phosphorus control [8]a sw e l la st h e
administration of large doses of vitamin D analogs for con-
trol of secondary hyperparathyroidism [40]m a yc o n t r i b u t e
to episodes of hypercalcemia and/or hyperphosphatemia
and may thus aggravate vascular calciﬁcation. Chertow
and coworkers have shown in a longitudinal study that
calcium-based phosphate binders are especially associated
with progressive coronary artery and aortic calciﬁcation in
hemodialysis patients when mineral metabolism is poorly
controlled [41]. Patients with low bone activity appeared to
be particularly susceptible to worsening of vascular calciﬁca-
tion and stiﬀening when exposed to an excess calcium load
[42]. This may be due to the inability of adynamic bone to
incorporate extra calcium load and thus increases the risk of
extraskeletal calciﬁcation.
6. Pathogenesis of Vascular/Valvular
Calciﬁcation
Vascular/valvular calciﬁcation is now recognized to be an
active, cellular-mediated process involving an osteogenic
phenotypic change of vascular smooth muscle cells along
with the dynamic interactions between calciﬁcation induc-
ers and inhibitors. Inﬂammation may act as one of the
potential stimulus for calciﬁcation. This is ﬁrst evident by
the accumulation of macrophages and T-lymphocytes other
than low-density lipoprotein and Lp(a) lipoprotein in early
aortic valve calciﬁcation [43, 44]. Subsequent study from our
group showed an important link between inﬂammation and
valvular calciﬁcation in PD patients [17]. Among patients
with high calcium ∗ phosphorus product, the presence of
both inﬂammation and malnutrition increased the preva-
lence of valvular calciﬁcation as compared to those with
no evidence of inﬂammation and malnutrition. Notably,
even among patients with normal calcium ∗ phosphorus
product, the presence of inﬂammation and malnutrition was
associated with at least twofold increase in the prevalence
of valvular calciﬁcation as compared to those with no
inﬂammation or malnutrition at all [17]. These data suggest
that inﬂammation is predictive of an increased risk of
valvular calciﬁcation independent of calcium ∗ phosphorus
product. The presence of inﬂammation also predicts a
more adverse clinical outcome among PD patients with
valvular calciﬁcation [45]. Histopathological study showed
markedly increased expression of C-reactive protein messen-
ger ribonucleic acid (mRNA) in the coronary vessels of renal
patients compared to nonrenal patients in both calciﬁed and
noncalciﬁed parts of arteries [29], suggesting that uremia
itself was associated with increased vascular inﬂammation
and that may mediate the development of vascular calciﬁca-
tion. This is further supported by in vitro data showing that
pooled uremic serum can induce accelerated calciﬁcation
of vascular smooth muscle cells, regardless of the level of
phosphorus. However, the exact uremic toxins that increase
vascular calciﬁcation are currently not clear. In hemodialysis
patients, C-reactive protein showed similar association with
annualized change in coronary artery calcium score [46]
and has been associated with progression of abdominal
calciﬁcation [47]. Inﬂammation has also been inversely
related to circulating fetuin-A or alpha-Heremans-Schmid
glycoprotein (AHSG) in both hemodialysis and PD patients
[48, 49]. These data add circumstantial evidence to support
possible causal link between inﬂammation and calciﬁcation
and warrant further investigation.
Circulating calciﬁcation inhibitors are increasingly rec-
ognized to play an important role in modifying the calci-
ﬁcation risk of ESRD patients. The presence of extensive
calciﬁcation in various organs including the kidneys, lungs,
myocardium, skin, and blood vessels in AHSG or fetuin-
A deﬁcient mice being fed a mineral and vitamin D rich
diet provides novel evidence to support a crucial role of
fetuin-A in inhibiting ectopic calciﬁcation [50]. Even though
some studies suggested higher fetuin-A levels in PD than
hemodialysis patients [51], lower serum fetuin-A was linked
to an increased risk of all-cause mortality and cardiovascular
death in both hemodialysis [48] and PD patients [49].
Lower fetuin-A was associated with more inﬂammation and
valvular calciﬁcation in PD patients [49]a n dw a si n v e r s e l y
related to more aortic calciﬁcation in pediatric dialysis
patients [52]. All these data lent supporting evidence that
fetuin-A may be involved in inhibiting vascular and valvular
calciﬁcation.
Other circulating inhibitor such as pyrophosphate has
recently been shown to be inversely related to the severity
of coronary artery calciﬁcation [53] and its circulating level
did not seem to be aﬀected by the severity of kidney
disease, the modality of dialysis or inﬂammatory activity
[53]. Matrix gla-protein (MGP) belongs to a family of the N-
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K-dependent γ-carboxylation for their biological activation.
The development of spontaneous vascular calciﬁcation in
MGP-deﬁcient mice was novel evidence to support a key
role of MGP in inhibiting vascular calciﬁcation [54]. A study
in the general population indicated an inverse correlation
between blood MGP levels and coronary artery calciﬁcation
[55]. However, the assay measured total blood levels of MGP
without diﬀerentiating between undercarboxylated (uc) and
carboxylated (cMGP) and without taking into account of tis-
sue deposition. More recently, study showed that serum total
uc-MGP was signiﬁcantly reduced in hemodialysis patients
compared to nonrenal failure population and markedly
reduced in patients with calciphylaxis [56]. Serum total uc-
MPG level was inversely correlated with serum phosphate
but positively associated with serum fetuin-A [57]. In a very
recent study, lower circulating levels of dephosphorylated-
carboxylated MGP (de-cMGP) was associated with more
inﬂammation and was predictive of higher mortality in
hemodialysis patients. Patients with lower dp-cMGP level
were also associated with more calciﬁcations as denoted
by a composite semiquantitative calciﬁcation score [58].
However, it remains further elucidation whether circulating
MGP directly reﬂects the biologically active MGP in the
vasculature and may play a causative role in vascular
calciﬁcation.
Osteoprotegerin (OPG) belongs to the tumor necrosis
factor-receptor gene superfamily and serves as a soluble
decoy receptor for the receptor activator of NF-κβ-ligand
(RANKL). It inhibits osteoclast activation and promotes
osteoclast apoptosis in vitro. The demonstration of medial
calciﬁcation of the aorta and renal arteries in OPG knockout
animal suggests OPG and its signaling pathway may play
a role in medial arterial calciﬁcation [59]. In the general
population, serum OPG was positively related to the extent
and severity of coronary artery disease [60]. Serum OPG
was higher in dialysis patients than healthy controls [52]
and was independently associated with the severity of
abdominal aortic calciﬁcation in hemodialysis patients [61].
Furthermore, both serum C-reactive protein and OPG were
higher among rapid progressors of abdominal calciﬁcation
compared to slow progressors [62]. Further study will be
required to investigate the exact role of OPG in vascular
calciﬁcation in ESRD patients.
Other potential mechanisms of vascular calciﬁcation
include vascular smooth muscle cells apoptosis and FGF-
23 and Klotho activity. There is in vitro evidence that
chronic mineral dysregulation is capable of triggering vas-
cular smooth muscle adaptation and release of matrix
vesicles and that ultimately culminates in vascular smooth
muscle cell apoptosis and vascular calciﬁcation [63, 64]. The
ﬁbroblast growth factor-23 (FGF-23)—klotho activity plays
an important role in the systemic regulation of phosphate
homeostasis [65, 66]. Studies have shown that both FGF-
23 and klotho knockout mice develop extensive vascular
and soft tissue calciﬁcation [67, 68]. Serum calcium and
1,25 hydroxyvitamin D levels are also elevated in both
Fgf23 and klotho ablated mice [69]. Moreover, increased
sodium phosphate cotransporter activity in both Fgf23 and
klotho ablated mice increases renal phosphate reabsorption
which in turn can facilitate calciﬁcation [68]. Very recent
study showed that Klotho may exert direct eﬀects on
vascular smooth muscle cells and its deﬁciency may directly
induce vascular calciﬁcation in uremia [70], suggesting that
Klotho may act as a novel circulating inhibitor of vascular
calciﬁcation.
7. Limiting the Progression of Vascular or
Valvular Calciﬁcation in PD Patients
Current therapeutic strategies for vascular/valvular calci-
ﬁcation in the ESRD population are largely linked to
management of mineral bone disorder associated with CKD
such as control of hyperphosphatemia, avoiding, hypercal-
cemia and control of secondary hyperparathyroidism. A
recent prospective analysis comparing 3555 patients who
began treatment with phosphorus binders during the ﬁrst
90 days after initiating hemodialysis versus 5055 patients
who remained untreated clearly showed that the early use
of phosphorus binders was independently associated with
better survival [71]. So far, there are no data as to whether
the type of phosphorus binders may aﬀect progression of
vascular calciﬁcation in PD patients. Study in PD patients
showed that sevelamer hydrochloride provides a similar
reduction in serum phosphorus compared to calcium-
based binders as in hemodialysis patients [72]. A number
of prospective open-label randomized controlled trials in
hemodialysis patients including the Treat to Goal study [11],
and the Renagel in New Dialysis Patients (RIND) study
[32], comparing sevelamer versus calcium-based binders
suggested a slower progression of coronary artery calciﬁca-
tion with sevelamer hydrochloride as compared to calcium-
based binders. Notably, in both studies [11, 32], sevelamer
and calcium-based binders-treated patients achieved com-
parable serum phosphorus control, but serum calcium was
signiﬁcantly lower in calcium-based binder-treated patients
versus sevelamer-treated patients. The reduced calcium load
with resulting lower serum calcium may partly contribute to
the slower progression of vascular calciﬁcation in sevelamer-
treated patients. In the extended followup of the RIND
study, a signiﬁcant survival beneﬁt was observed in the
sevelamer-treated patients as compared to patients treated
with calcium-based binder [5]. On the other hand, the
Calcium Acetate Renagel Evaluation-2 (CARE 2) study
reported similar progression of coronary artery calciﬁcation
with sevelamer and calcium acetate when statins were used
to achieve a similar serum LDL-cholesterol in hemodialysis
patients [73]. In the Dialysis Clinical Outcomes Revisited
(DCOR) study, no signiﬁcant diﬀerence was observed in the
overall all-cause mortality between sevelamer and calcium-
based binder treated hemodialysis patients. However, there is
some suggestion that sevelamer treatment may be associated
with lower overall mortality but not cardiovascular-related
mortality among elderly patients [74] .T h e r ei sn od a t ao n
the eﬀect of lanthanum carbonate or other newer phos-
phorus binders on the progression of vascular calciﬁcation
as compared to calcium-based binders in dialysis patients.
Given the current available evidence, the Kidney Disease
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restricting thedose ofcalcium-basedbinders inpatients with
stage 5D CKD including those on PD, in the presence of
persistent or recurrent hypercalcemia, arterial calciﬁcation,
adynamic bone disease, and persistently low parathyroid
hormone [75].
Vitamin D receptor activator (VDRA) has been the
standard treatment for secondary hyperparathyroidism in
patients with CKD. There is animal data to suggest that
diﬀerent VDRAs have diﬀerential eﬀects on vascular calci-
ﬁcation in uremia [40]. In the study by Mizobuchi et al.,
paricalcitol, a selective VDRA, showed no eﬀects on serum
calcium, phosphorus and aortic calcium content in uremic
a n i m a l si nc o n t r a s tt oo t h e rV D R As u c ha sc a l c i t r i o lo r
doxercalciferol which increased serum calcium, phosphorus,
and aortic calcium content. In addition, doxercalciferol
treatment increased mRNA and protein expression of bone-
related markers Runx2 and osteocalcin in the aorta, while
paricalcitol did not [40]. Similar data suggest diﬀerential
eﬀects of paricalcitol and calcitriol on aortic wall remodeling
in uninephrectomized Apo-E knockout animals [76]. There
are observational data to suggest that use of paricalcitol
was associated with survival advantage over calcitriol in
hemodialysis patients [77]. Randomized controlled trials
will be required to determine whether paricalcitol may be
associated with less progression of vascular calciﬁcation
compared to other VDRA in the dialysis population.
Cinacalcet hydrochloride is a calcimimetic agent that
inhibits parathyroid hormone secretion from the parathy-
roid cells by activation of the Ca receptor and emerges as
a novel therapeutic agent for the treatment of secondary
hyperparathyroidism in patients with CKD [78]. Previous
double-blind randomized placebo-controlled trial showed
that cinacalcet had comparable eﬃcacy in both hemodialysis
and PD patients and eﬀectively reduced calcium, phospho-
rus, and parathyroid hormone [79]. In the more recent
33-week ACHIEVE study that randomized hemodialysis
patients to receive either cinacalcet and low-dose vitamin
D analog or ﬂexible vitamin D analog, a more signiﬁcant
reduction in parathyroid hormone (PTH) (median percent
change, −47% versus −11%), calcium, and phosphorus
was observed in the cinacalcet and low-dose vitamin D
analog treatment group as compared to ﬂexible vitamin
D analog group [80]. Studies in uremic animal models
showed that calcimimetic is capable of inhibiting vascular
calciﬁcation in contrast to calcitriol which induces vascular
calciﬁcation [81, 82]. In the ADVANCE trial, a prospective,
randomized, controlled trial that evaluated the progression
of vascular and cardiac valve calciﬁcation in 360 prevalent
adult hemodialysis patients with secondary hyperparathy-
roidism after receiving treatment with cinacalcet plus low-
dose vitamin D sterols versus ﬂexible doses of vitamin D
sterols alone, a trend towards less progression of coronary
arteryAgatstoncalciumscorewasobservedinthecinacalcet-
treated group after 52 weeks versus the ﬂexible vitamin
D sterol group but did not reach statistical signiﬁcance.
The diﬀerence in the corresponding changes in volume
scores between the two groups were, however, of statistical
signiﬁcance. Furthermore, increases in calcium scores were
consistently less in the aorta, aortic valve and mitral valve
amongsubjectstreatedwithcinacalcetpluslow-dosevitamin
Ds t e r o l sv e r s u st h eﬂ e x i b l ev i t a m i nDs t e r o lg r o u p ,a n dt h e
diﬀerences were signiﬁcant at the aortic valve [83]. These
data suggest that the use of cinacalcet may be associated
with slower progression of vascular/valvular calciﬁcation as
compared to ﬂexible vitamin D sterol-treated patients. We
await the results of another randomized trial, namely, the
EVOLVE (evaluation of cinacalcet HCl therapy to lower
cardiovascular events) study to investigate whether cinacal-
cet treatment may confer survival beneﬁt in hemodialysis
patients with secondary hyperparathyroidism. There is so
far no randomized controlled study in PD population that
addresses the issue of vascular/valvular calciﬁcation and
clinical outcomes in relation to VDRA or cinacalcet. Thus,
we can only lend support from data in hemodialysis patients.
Studies in in vitro cell culture model or ex vivo model
suggested that aortic calciﬁcation requires the elevation
of both calcium and phosphorus and that calcium rather
than phosphate appears to have a more profound eﬀect on
aortic calciﬁcation [63, 84]. However, in PD patients, a low
calcium PD ﬂuid may be associated with exacerbation of
secondary hyperparathyroidism [85]. Thus, to help reduce
calcium loads yet without exacerbating secondary hyper-
parathyroidism, the previous K/DOQI guideline suggested
that the dialysate calcium concentration in hemodialysis
or PD should be maintained at 2.5meq/L (1.25mmol/L)
[86]. The more recent 2009 KDIGO guideline suggested that
the dialysate calcium concentration in hemodialysis or PD
patients should be between 2.5 (1.25mmol/L) and 3mEq/L
(1.5mmol/L) [75]. A dialysate calcium concentration above
3meq/L (1.5mmol/L) is not recommended in dialysis
patientsasitresultsinpositivecalciumbalanceandincreased
risk of hypercalcemia [87]. Therefore, maintaining a neutral
calcium balance appeared a reasonable goal in managing
PD patients. There is so far very little data on the eﬀect of
dialysate calcium concentration on vascular calciﬁcation in
PD patients. A small nonrandomized study suggested that
patients receiving PD ﬂuid of high calcium concentration,
namely 1.75mmol/L showed an increase in arterial stiﬀening
as compared to those using low calcium concentration PD
ﬂuid which showed no change [88]. These preliminary data
suggest that high calcium exposure through PD solution
may play a role in progressive arterial stiﬀening through
an increase in vascular calciﬁcation and warrant further
investigation.
8. Conclusions
Vascular and valvular calciﬁcations are equally highly preva-
lentinESRDpatientsreceivingPDtreatmentasinhemodial-
ysis patients and are predictive of an increased mortality
and adverse cardiovascular outcomes. Current therapeutic
strategies that may be of use in limiting progressive vascu-
lar/valvular calciﬁcation in PD patients are largely linked to
management of mineral bone disorder associated with CKD
including control of hyperphosphatemia, avoiding hyper-
calcemia, and control of secondary hyperparathyroidism.
Randomized controlled trials will be required to determine6 International Journal of Nephrology
whether these strategies may reduce calciﬁcation burden and
clinical outcomes in the PD population.
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